Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Operator of a pioneering private biotech company intended for vivo direct cell reprogramming for cancer immunotherapy. The company's proprietary reprogramming technologies develop gene therapy products that ignite efficient and personalized immune responses to establish a robust pipeline of off-the-shelf cancer immunotherapies, activating personalized anti-cancer immune defenses for the benefit of patients in need by offering new treatment avenues for cancers resistant to conventional methods, enabling patients to acquire new forms of treatment for cancer resistant to conventional treatment methods.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Hemab
Series A in 2021
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Chromologics ApS is a Danish biotechnology company based in Søborg, founded in 2017 as a spin-out from the Technical University of Denmark. The company specializes in the development of bio-based solutions for natural food colorants, with a focus on innovative products that can replace existing natural colorants like carmine and betanin. Chromologics has created a fungal biotechnology platform to produce its flagship product, ChromoRed, which represents a new generation of natural red food colorants. Through its advancements, Chromologics aims to provide sustainable alternatives in the food industry.
AMSilk GmbH, based in Munich, Germany, specializes in producing spider silk proteins and biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film used for protective coatings in medical devices, as well as biosteel spider silk fibers. AMSilk also develops over-the-counter wound care products like SanaSilk, designed to protect the skin, and provides spider silk-based solutions for surgical applications. Additionally, the company produces spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Its offerings include both raw materials and semi-finished products such as membranes and films. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company was founded in 2008.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
Hemab
Seed Round in 2020
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
The Protein Brewery is a high-tech company that specializes in developing and making animal-free- based protein in a sustainable way. It's a spin-out from BioscienZ and is commercializing innovative protein production using fermentation. It was founded by Wim de Laat in 2019 and is based in Breda, Noord-Brabant, The Netherlands.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
Rappta Therapeutics Oy engages in developing anti-cancer drugs that activate protein phosphatase 2A (PP2A). Protein phosphatase 2A (PP2A) is a critical enzyme regulating protein de-phosphorylation and tumor growth. The company was incorporated in 2019 and is based in Helsinki, Finland with an additional office in the United States.
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.
Lava Therapeutics was established in 2016 and is headquartered in Utrecht, The Netherlands.
Chromologics ApS is a Danish biotechnology company based in Søborg, founded in 2017 as a spin-out from the Technical University of Denmark. The company specializes in the development of bio-based solutions for natural food colorants, with a focus on innovative products that can replace existing natural colorants like carmine and betanin. Chromologics has created a fungal biotechnology platform to produce its flagship product, ChromoRed, which represents a new generation of natural red food colorants. Through its advancements, Chromologics aims to provide sustainable alternatives in the food industry.
Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipid uptake in adipose tissue in an efficient manner.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, focused on developing innovative drugs for the treatment of acute and chronic liver diseases. Founded in 2016, the company’s therapeutic approach is centered on a proprietary molecular target known as Mitogen-Activated Protein (MAP) Kinase 4. Research conducted by Professor Lars Zender and his team at the University Hospital Tübingen highlighted MKK4 as a crucial regulator of liver regeneration. Their findings indicated that small RNA molecules could suppress MKK4 gene expression, thereby restoring the regenerative capacity of hepatocytes even in severely affected livers. HepaRegeniX is specifically working on small-molecule inhibitors of MKK4, with potential applications in treating conditions such as nonalcoholic steatohepatitis.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Envirotainer AB is engaged in the production, development, and rental of active temperature-controlled containers for air transportation of temperature-sensitive healthcare products in Sweden and internationally. It also provides various services, including laboratory testing, qualification and validation support, data collection and reporting, and the Qualified Envirotainer Program for training. The company’s client list includes pharmaceutical and biotech companies. The company was founded in 1986 and is based in Upplands Väsby, Sweden with operations centers in Singapore; Dallas, Texas; Frankfurt, Germany; and Toronto, Canada. It also has a network stations in Hyderabad, India.
Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, established in 2017. The company specializes in the development and manufacturing of novel therapeutics aimed at addressing metabolic, inflammatory, and fibrotic diseases. It focuses on creating first-in-class, oral lipid therapeutics through its proprietary Structurally Engineered Fatty Acid (SEFA) technology. One of its key products, icosabutate, is a structurally engineered fatty acid designed to treat inflammatory and liver diseases. The SEFA technology enables the development of candidates that exhibit a range of biological effects, effectively targeting issues such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis across various models.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipid uptake in adipose tissue in an efficient manner.
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
AMRA is an international medical technology company, the first in the world to transform MR images into precise body composition measurements using a cloud-based, computer-aided service.They collaborate with world-leading pharmaceutical organizations, biobanks and population cohorts, research institutions, hospitals, and clinics, aiding in the advancement of metabolic research and therapeutic application. With more accurate knowledge about our bodies, AMRA assists the world's medical leaders in predicting and preventing disease.
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, focused on developing innovative drugs for the treatment of acute and chronic liver diseases. Founded in 2016, the company’s therapeutic approach is centered on a proprietary molecular target known as Mitogen-Activated Protein (MAP) Kinase 4. Research conducted by Professor Lars Zender and his team at the University Hospital Tübingen highlighted MKK4 as a crucial regulator of liver regeneration. Their findings indicated that small RNA molecules could suppress MKK4 gene expression, thereby restoring the regenerative capacity of hepatocytes even in severely affected livers. HepaRegeniX is specifically working on small-molecule inhibitors of MKK4, with potential applications in treating conditions such as nonalcoholic steatohepatitis.
Hoba Therapeutics
Seed Round in 2016
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Battersea Biotech
Seed Round in 2016
Battersea Biotech develops alternative cell types and technologies to overcome the shortcomings of current CAR-T and TCR technologies.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Reapplix A/S manufactures device for cell therapy that helps patients in wound healing. It offers 3C Patch, a triple layer patch that consists of fibrin for moisture retention and strength, platelets for growth factor release, and leucocytes to orchestrate wound healing and to fight infection. The company was formerly known as Reapplix ApS and changed its name to Reapplix A/S in December 2018. Reapplix A/S was founded in 2008 and is based in Birkerød, Denmark with an additional office in Southlake, Texas.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, that specializes in developing biocatalysts for the fermentation of fine chemicals. Founded in 2012, the company utilizes a patent-pending high-throughput screening technology to create biocatalysts with remarkable speed and efficiency. By focusing on tailored biocatalytic processes, Biosyntia enables the production of complex chemical compounds through fermentation, significantly reducing both production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers of fine chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives, to promote sustainable manufacturing practices and contribute to a greener future. Biosyntia is located at the Novo Nordisk Foundation Center for Biosustainability, approximately 25 kilometers north of Copenhagen.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Glionova AB is a biopharmaceutical company based in Stockholm, Sweden, focused on developing therapies for challenging cancers. Founded in 2014, the company is working on GLN-1001, an orally bioavailable small molecule designed to selectively induce cell death in glioblastoma cells while sparing normal brain tissue. This innovative approach aims to improve treatment outcomes for patients suffering from glioblastoma, a common and aggressive form of primary brain tumor. In addition to its core product development, Glionova seeks to establish strategic partnerships with global pharmaceutical companies that specialize in oncology to enhance its market presence and advance its therapeutic offerings.
Forendo Pharma is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapies for urological and endocrinological diseases, focusing on tissue-specific regulation of sex hormone mechanisms. Its primary product, Fispemifene, is a selective estrogen receptor modulator designed to address the symptoms of low testosterone in men. Additionally, Forendo Pharma is developing a 17HSD1-inhibitor targeting endometriosis, which aims to meet unmet medical needs in both women's and men's health. Through its innovative approach, Forendo Pharma seeks to enhance treatment options for a range of gynecological and urological conditions.
Pulmologix AB develops, manufactures, and sells oral non-steroidal anti-asthmatic drug for the treatment of early onset allergic asthma. The company was founded in 2006 and is based in Stockholm, Sweden.
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders .
Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. It develops and produces cultures, enzymes, probiotics, and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements, and even animal feed. All solutions are based on strong research and development competencies coupled with significant technology investments. Chr. Hansen has more than 2,500 employees in 30 countries and main production facilities in Denmark, France, USA, and Germany. It was founded in 1874 and is listed on Nasdaq Copenhagen.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.
Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011, focused on developing and commercializing innovative antibiotics to address multi-drug resistant bacterial infections. The company specializes in solutions for hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its lead product, Arenicin, is a non-toxic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against gram-negative pathogens. Adenium Biotech employs a semi-virtual model, leveraging a small team of experts and an international scientific advisory board to advance the Arenicin program through clinical development towards regulatory approval. The company's goal is to provide effective treatments for infections that are increasingly difficult to manage due to antibiotic resistance.
Nanoference
Venture Round in 2010
Nanoference ApS develops technology that uses nano particles to deliver Sirna molecules directly to the desired part of the body. The company was founded in 2009 and is based in Aarhus, Denmark.
Archimedes Pharma Limited operates as a specialty pharmaceutical company. Its products include Gliadel, for high grade glioma; Zomorph, an oral sustained release morphine product for cancer pain; Nozinan that treats nausea and vomiting in cancer patients; Pabrinex, a formulation of vitamins B and C for alcoholics experiencing acute withdrawal; and Nasalfent, an intranasal fentanyl for relief of cancer pain. The company was founded in 2004 and is headquartered in Reading, the United Kingdom. It has operations in the United Kingdom, France, and Germany.
7TM Pharma
Series D in 2007
7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, gastrointestinal, metabolic, asthma, and vascular diseases. The company offers seven transmembrane-spanning receptors, including TM38837, a small molecule CB1 receptor antagonist; TM30339, a NPY Y4 selective agonist that is used within gastrointestinal disorders, and short bowel syndrome; and CRTH2 antagonist, an oral drug for inflammatory or respiratory diseases. 7TM Pharma was founded in 2000 and is based in Lyngby, Hovedstaden.
Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.
Celltrix is a Swedish biotechnology/medical device company focusing on reconstructive cosmetic surgery. Research, development and production are based in Malmö. They plan to launch the first product —Credurance — in 2010. Their product represents a new type of dermal filler. An immediate filling effect is achieved and the surrounding cells are presented to a matrix suitable for cell growth. As the cells grow on and inside the matrix, they produce their own environment, natural collagen, which gradually replaces the matrix – biorestoring.
Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.
Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.
Nuevolution AB is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. It specializes in developing drug treatments for oncology and chronic inflammatory diseases, leveraging its unique Chemetics platform for drug discovery. This platform combines proven wet chemistry and molecular biology, allowing for the synthesis and screening of over one billion small molecule compounds and synthetic biologics. Nuevolution is focused on several therapeutic programs, including ROR?t inhibitors and IL-17A inhibitors for chronic inflammatory diseases, as well as GRP78 for oncology. The company has established collaborations with notable pharmaceutical partners, including Amgen and Janssen Biotech, and is involved in joint ventures aimed at discovering novel small molecule drugs targeting epigenetic factors. Through its innovative technology, Nuevolution aims to address significant unmet medical needs in various therapeutic areas.
Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.
Fisher BioImage
Series B in 2002
Fisher BioImage ApS, a life science company, develops and sells assays for monitoring protein translocations and protein interactions in living cells. It provides Redistribution technology, which helps to monitor cell-based protein translocation assays using fluorescent protein reporters. The company offers assays to pharmaceutical and biotechnology companies, as well as to academic groups for basic research.
Nuevolution AB is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. It specializes in developing drug treatments for oncology and chronic inflammatory diseases, leveraging its unique Chemetics platform for drug discovery. This platform combines proven wet chemistry and molecular biology, allowing for the synthesis and screening of over one billion small molecule compounds and synthetic biologics. Nuevolution is focused on several therapeutic programs, including ROR?t inhibitors and IL-17A inhibitors for chronic inflammatory diseases, as well as GRP78 for oncology. The company has established collaborations with notable pharmaceutical partners, including Amgen and Janssen Biotech, and is involved in joint ventures aimed at discovering novel small molecule drugs targeting epigenetic factors. Through its innovative technology, Nuevolution aims to address significant unmet medical needs in various therapeutic areas.